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Abstract
Objective: To compare the clinical outcomes and cost-effectiveness of routine HIV screening in Portugal to the
current practice of targeted and on-demand screening.
Design: We used Portuguese national clinical and economic data to conduct a model-based assessment.
Methods: We compared current HIV detection practices to strategies of increasingly frequent routine HIV screening
in Portuguese adults aged 18-69. We considered several subpopulations and geographic regions with varying levels
of undetected HIV prevalence and incidence. Baseline inputs for the national case included undiagnosed HIV
prevalence 0.16%, annual incidence 0.03%, mean population age 43 years, mean CD4 count at care initiation 292
cells/μL, 63% HIV test acceptance, 78% linkage to care, and HIV rapid test cost €6 under the proposed routine
screening program. Outcomes included quality-adjusted survival, secondary HIV transmission, cost, and incremental
cost-effectiveness.
Results: One-time national HIV screening increased HIV-infected survival from 164.09 quality-adjusted life months
(QALMs) to 166.83 QALMs compared to current practice and had an incremental cost-effectiveness ratio (ICER) of
€28,000 per quality-adjusted life year (QALY). Screening more frequently in higher-risk groups was cost-effective: for
example screening annually in men who have sex with men or screening every three years in regions with higher
incidence and prevalence produced ICERs of €21,000/QALY and €34,000/QALY, respectively.
Conclusions: One-time HIV screening in the Portuguese national population will increase survival and is cost-
effective by international standards. More frequent screening in higher-risk regions and subpopulations is also
justified. Given Portugal’s challenging economic priorities, we recommend prioritizing screening in higher-risk
populations and geographic settings.
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Introduction
By comparison to its European neighbors, Portugal bears an
unusually severe HIV/AIDS burden. Its overall HIV/AIDS
prevalence is 0.53% [1,2]. Incidence estimates range from
0.005% to 1.08% per year, depending on risk group, and
Portugal has the second highest incidence rate in the
European Union [3]. Late presentation is common: 30.7% of
newly detected individuals have already advanced to AIDS [1].
The Portuguese National Health Service provides universal
coverage for HIV testing and care. To encourage earlier
detection of infection and initiation of HIV care, the Portuguese
parliament recently adopted a resolution to expand routine,
population-based HIV testing [4]. This policy mirrors the
recommendations of the World Health Organization (WHO), the
United States Centers for Disease Control and Prevention, and
the French Haute Autorité de Santé [5–7].
Portugal faces numerous challenges in implementing this
resolution. Most notable among these is the current economic
crisis. Portugal’s Gross Domestic Product (GDP) per capita
(€15,600) is among the lowest in Western Europe; in 2010,
debt service accounted for 33% of the overall National Health
Service budget [8]. In the face of these challenges, we sought
to estimate the survival benefits, costs, and cost-effectiveness
of alternative approaches to expanded HIV screening in
Portugal.
Methods
Analytic Overview
We compared four strategies for HIV screening in
Portuguese adults aged 18-69: 1) current practices of detection
(notably non-routine, provider- or patient-initiated testing and
presentation with opportunistic infections); versus current
practices with the addition of 2) routine one-time screening; 3)
routine screening every three years; and 4) routine annual
screening. Given the geographic and demographic
heterogeneity of the HIV/AIDS epidemic in Portugal, we also
examined both regionally targeted screening and strategies
focused on high-risk injection drug users (IDUs) and men who
have sex with men (MSM).
We used the Cost-Effectiveness of Preventing AIDS
Complications (CEPAC) model, a widely-published
microsimulation of HIV disease, to forecast mean costs, life-
expectancy, and quality-adjusted life expectancy in months
(QALM) in both HIV-infected and HIV-uninfected individuals
under each strategy [9–17]. These estimates take into account
the impact of the intervention on secondary HIV infection.
Comparative value used the incremental cost-effectiveness
ratios (ICERs), measured in both euros per year of life saved
(€/YLS) and euros per quality-adjusted life-year saved (€/
QALY). We applied the guidance of the WHO Commission on
Macroeconomics and Health, which suggests that an
intervention be labeled “cost-effective” in a given country if its
ICER is less than three times the nation’s per capita GDP [18].
Since the Portuguese GDP is €15,600, programs delivering
QALYs for less than €46,800 were deemed “cost-effective.”
Because our goal was to inform decision making at the level of
the Portuguese National Health Service, we conducted our
analyses from a modified societal perspective (excluding
indirect costs), and discounted costs, life expectancy, and
quality adjusted life expectancy at 5% per annum [19].
CEPAC Model
Disease Model.  The Cost-Effectiveness of Preventing AIDS
Complications (CEPAC) model presents the natural history,
treatment, and costs of HIV disease [9–17]. The model portrays
disease progression as a sequence of monthly transitions
between “health states.” Each simulated patient is followed
monthly in the model until death [9–17]. The progression of HIV
disease is determined by CD4 count, HIV RNA level, and
history of opportunistic infection. Patients receiving ART have
reduced HIV RNA, increased CD4 count, and protection from
opportunistic infection (OIs) [20]. Morbidity is calculated as a
single outcome measure that expresses survival while
accounting for quality of life [10,19,21,22]. Further details on
the structure of the CEPAC model have been reported
elsewhere [9–13]. The CEPAC model has been used to
estimate the cost-effectiveness of expanded screening
programs in the United States, South Africa, and France
[12–15,17].
Screening Module.  While the Disease Model described
above simulates the course of HIV illness for all infected
individuals, only patients with detected HIV infection who are
successfully linked to care are eligible for clinic visits, OI
prophylaxis, and antiretroviral therapy [12–15,17,23]. The
Screening Module uses information on HIV prevalence,
incidence, testing behavior, and HIV test performance to
determine eligibility for treatment and conveys that information
to the Disease Model. Persons in the Screening Module may
either be HIV-uninfected or HIV-infected; the infected
population is further separated into prevalent cases (persons
infected at the time of model initialization [t=0]) and incident
cases (whose infection occurs after model initialization). HIV
detection takes place via one of three mechanisms: a)
“background HIV testing,” defined as Portugal’s current non-
routine testing practice; b) presentation to clinic with an AIDS-
defining OI; or c) expanded, routine HIV screening. HIV is
currently diagnosed in Portugal via one of the first two
detection mechanisms. (Further details on the Screening
Module are provided in Appendix S1.)
Transmission Module.  The Transmission Module uses
deterministic methods to link the effects of expanded HIV
screening and earlier treatment initiation to both community
HIV RNA levels and the subsequent number and timing of
secondary HIV infections. The Transmission Module maintains
a running tally of both the size of the susceptible (i.e.
uninfected) population and the aggregate level of HIV RNA
among infected (treated and untreated) persons. These are
then combined with both Portuguese incidence data and HIV
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RNA-specific transmission rates from a variety of meta-
analyses and modeling studies to estimate the number of new
HIV transmissions in subsequent periods [1,24,25]. The
Transmission Module permits us to estimate the impact of
alternative HIV screening policies on transmissions from index
cases to uninfected members of the population (i.e., first-order
transmissions). By applying average discounted survival
outcomes and costs from the CEPAC Disease Model to new
infections, it also permits us to include the effects of secondary
transmission in our cost-effectiveness estimates. (For further
details on the Transmission Module, see Appendix S1.)
Input Data
Values for the key parameters used in our baseline
assessment and plausible ranges we developed for the
extensive sensitivity analyses are shown in Table 1. Further
details on the protocols we used to assemble, develop, and
validate these estimates are available in Appendix S1.
Cohort Sociodemographic Characteristics.  The baseline
characteristics of the simulated cohort represent the
Portuguese population aged 18 to 69 years old. The national
population had a mean age of 43 years and was 49% male
[26]. The MSM population had a mean age of 35 years (range
17-79 years) [27]. The IDU population had a mean age of 31
years (range 18-49). The IDU population was 71% male [28].
Disease Progression and Mortality.  Recognizing the
limited availability of Portuguese data on HIV natural history,
we developed estimates using a combination of national and
international sources and then subjected all estimates to
extensive sensitivity analysis. Data from two French clinical
cohorts were employed to estimate CD4-stratified OI incidence
and HIV-related mortality rates [29]. National age- and gender-
stratified mortality rates unrelated to HIV/AIDS were first
obtained from Portuguese sources. These were further
adjusted for MSM and IDUs using previously published age-
and gender-stratified mortality ratios for these sub-populations
[26,30].
Treatment.  Simulated patients who were HIV diagnosed
and effectively linked to care were assumed to receive CD4
count and HIV RNA measurements every four months [31]. In
accordance with Portuguese national guidelines, patients who
were HIV diagnosed and successfully linked to care received
ART when their CD4 count was below 350 cells/μL or when
they had a WHO Stage III or IV OI [31]. ART regimens were
switched when patients were observed to have experienced
virologic failure, defined as an HIV RNA rebound to pre-ART
levels. Values for ART and OI prophylaxis efficacies were
obtained from published randomized controlled trials (Table 1)
[32–37]. Because these outcomes were derived from intention-
to-treat analyses, we assumed that adherence to prophylaxis
was comparable to the level of adherence observed in the
clinical trials. The level of adherence to ART in clinical trials
may be higher than in non-trial settings. As a result we may
have overestimated ART effectiveness. However, lower
efficacies, in particular for ART, were considered in the
sensitivity analysis.
Costs and Quality of Life.  Data on resource use for non-
ART routine medical care and death were obtained from a
survey of 5 Portuguese National Health System (NHS)
hospitals [38]. ART regimen unit costs were the official prices
paid by NHS hospitals and were obtained from the official
Central Administration of the Health System (ACSS)
procurement list [39]. Laboratory test unit costs were obtained
from the Portuguese official tariffs. Unit costs for consultations
were obtained from the Analytical Accounting of NHS Hospitals
[40]. Quality of life values for given model events and health
states were derived from published studies of health state
utilities in HIV-infected patients [41,42]. All costs were
converted to 2012 Euros [43].
HIV Prevalence and Incidence.  Prevalence was derived
using data from the National Institute for Health (INSA), the
Portuguese agency responsible for completing compulsory
data collection of HIV-positive diagnoses [1]. INSA reported a
prevalence of 0.37% diagnosed cases in 2008. Applying a
European report that 30% of all HIV cases are undiagnosed [2],
we estimated a prevalence of undiagnosed HIV of 0.16% and
an overall national prevalence of 0.53%. Prevalence data were
obtained for twenty different country regions as well as for
MSM and IDUs [1]. National and regional annual incidence
rates for the national population and these sub populations
were obtained from INSA and stratified by age by applying
incidence rate ratios from a study of HIV incidence in the
United States [1,44]. (The methods used to calculate risk group
incidence are described in Appendix S1.)
Characteristics of “Background Testing”.  In Portugal,
HIV testing is performed on demand, and routinely proposed to
pregnant women, patients with tuberculosis and sexually
transmitted infections, and prisoners. Data from five large
Portuguese hospitals, representing 38.1% of HIV patients in
care in Portugal indicated that, for the year 2008, the mean
CD4 count for all patients initiating HIV care with current testing
practices was 292 cells/uL (SD 282) [38]. Mean CD4 at
presentation to care for MSM (347 cells/μL (SD 336)) and IDUs
(269 cells/μL (SD 260)) was derived by applying ratios from a
French study that examined screening rates among the French
national population, MSM and IDUs [17].
To determine the delay from infection to initiation of HIV care
for the national population, we ran simulations where we
offered no routine HIV screening and varied the non-routine
screening rate. When we set the non-routine screening rate to
once every 66 months, the mean CD4 count at presentation to
care was 293 cells/μL, which closely approximates Portuguese
surveillance data. This delay suggests a 1.52% constant
monthly probability of background HIV testing, diagnosis and
linkage to care. We repeated the same analysis for MSM and
IDUs and determined that background testing occurs once
every 39 months among MSM and once every 90 months
among IDUs.
To offer a conservative portrayal of the incremental benefits
of expanded, routine HIV screening, we adopted a favorable
view of background testing performance: 100% test sensitivity;
100% test specificity; and immediate linkage to care for 100%
of detected cases. Doing so had the effect of understating the
incremental benefits and cost-effectiveness of routine HIV
testing, hence biasing the analysis against our own
conclusions. Any retreat to a less favorable view of current
Routine HIV Screening in Portugal
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Table 1. Input Parameters for a Model of Routine HIV Screening in Portugal.
Parameter Baseline Value Range for Sensitivity Analyses Source
Cohort Characteristics
Mean age (SD), years, national population 43 (14) 38-48 [26]
Mean age (SD), years, MSM population 35 (12) -- [27]
Mean age (SD), years, IDU population 31 (10) -- [28]
Men, % of patients, national population 49 -- [26]
Men, % of patients, IDU population 71 -- [28]
Efficacy of ART (% patients with HIV RNA suppression at 24 weeks)
1st Line ART 86 73-99 [32]
2nd Line ART 73 62-84 [37]
3rd Line ART 61 52-70 [37]
4th Line ART 65 55-75 [33]
5th Line ART 40 34-46 [35,36]
6th Line ART 15 13-17 [35]
Treatment costs, 2012 €
1st Line ART 780 550-1,014 [39]
2nd Line ART 995 697-1,294 [39]
3rd Line ART 1,072 750-1,394 [39]
4th Line ART 1,569 1,098-2,040 [39]
5th Line ART 2,259 1,581-2,937 [39]
6th Line ART 888 622-1,154 [39]
Prevalence of undiagnosed HIV, %
National population 0.16 0.03-0.30 [1,2]
IDUs 6.69 -- [2,54]
MSM 3.34 -- [2,55]
Annual incidence rate, %
National population 0.03 0.01-0.04 [1]
IDUs 1.08 --  
MSM 0.43 --  
Mean CD4 count (SD) at HIV care initiation in the “current practice” scenario, cells/μL
National population 292 (282) -- [38]
IDUs 269 (260) -- [38,56]
MSM 347 (336) -- [38,56]
Testing behavioral characteristics of proposed routine HIV screening program
Probability of test offer, % 80 -- Assumption
Probability of test acceptance, % 79 32-100* [47]
Probability of linkage to care, % 78 20-100 [48]
Costs associated with routine HIV screening program, 2012 €
HIV test cost 6 6-37 [49]
Confirmatory test (blood draw, Western Blot) 102 -- [49]
Post-test counseling costs for HIV+ patients 32 -- [49]
Secondary transmission rate for heterosexuals and IDUs stratified by plasma HIV RNA (copies/mL),/100 person-years
> 50,000 9.0 3.9-21.1 [24]
10,000-49,999 8.1 2.8-23.8 [24]
3,500-9,999 4.2 0.8-20.7 [24]
400-3,499 2.1 0.6-7.5 [24]
<400 0.2 0.0-1.1 [24]
Secondary transmission rate for MSMs stratified by plasma HIV RNA (copies/mL),/100 person-years
> 50,000 72.2 -- [24,25]
10,000-49,999 65.0 -- [24,25]
3,500-9,999 33.4 -- [24,25]
400-3,499 16.5 -- [24,25]
<400 1.6 -- [24,25]
Routine HIV Screening in Portugal
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practice would only serve to strengthen the findings reported
below [45,46].
Characteristics of Routine Screening Program.  For
routine HIV screening in all settings and risk groups, we used a
test offer rate of 80%, a test acceptance rate of 79%, and a
linkage to care rate of 78% [47,48]. Testing was performed
using a rapid HIV test without pre-test counseling, at a cost of
€6 [49]. Patients with a positive result returned for a physician
consult, a blood draw and confirmatory Western blot, with a
total cost of €102 [49]. This physician visit included post-test
counseling and linkage to care. We varied these parameters
widely in sensitivity analyses for all three groups.
Secondary HIV Transmission.   For the national, regional
and IDUs analyses, the estimated rate of HIV transmission
ranged from 0.2/100 PY at HIV RNA levels <400 copies/mL to
9.0/100PY at HIV RNA levels >50,000 copies/mL. These
values were derived from a meta-analysis of 11 studies that
followed a total of 5,021 heterosexual couples with 461
observed HIV transmission events in eight countries [24]. For
the MSM analysis, we assumed that transmission occurred at
eight times the rate it does in the heterosexual population [25].
Results
Base Case – National Program
Under the “current practice” scenario, the discounted quality-
adjusted life expectancy is 194.31 QALMs (undiscounted
464.86 QALMs) and the discounted per-person HIV-related
costs are €630 for the national population (includes HIV-
uninfected and HIV-infected people). In the HIV-infected
population, the mean CD4 count at diagnosis is estimated at
293 cells/μL, and the discounted quality-adjusted life
expectancy of HIV-infected persons is 164.09 QALMs
(undiscounted 367.76 QALMs), (Table 2).
After the addition of a one-time routine HIV screen to current
practice, the quality-adjusted life expectancy is 194.32 QALMs
(undiscounted 464.90 QALMs), and the average discounted
lifetime HIV-related costs are €680/person, for the general
population. The addition of a one-time routine HIV screen
increases mean CD4 count at diagnosis to 306 cells/μL, and
the quality-adjusted life expectancy to 166.83 QALMs
(undiscounted 373.36 QALMs). The ICER of one-time
screening compared to current practice is €30,000/QALY if one
does not account for secondary transmission and €28,000/
QALY if one does account for secondary transmission. This
suggests that one-time screening is cost-effective (ICER less
than €46,800, or three times Portuguese GDP).
Screening patients every three years or annually further
increases survival and costs. The ICERs for screening every
three years are €50,000/QALY and €44,000/QALY, excluding
and including secondary transmission, respectively. The ICER
for annual screening is €65,000/QALY if secondary
transmission is not considered and €59,000/QALY if it is
considered. All further ICERs presented include the impact of
secondary transmission.
Regional Analysis
Compared to current practice, the addition of a one-time,
routine HIV screening is cost-effective in each of the 20
different regions of Portugal (Table 3), with ICERs ranging from
€27,000 to €38,000 per QALY. In six regions (Açores, Madeira,
Porto, Faro, Setúbal, and Lisboa), increasing the screening
frequency to every three years is also cost-effective, with
ICERs ranging from €34,000 to €43,000 per QALY. Annual
screening is not cost-effective in any of the regions.
Risk Group Analysis
Among MSM, compared to current practice, not only one-
time routine HIV-screening, but also annual screening is cost-
effective (undiagnosed prevalence 3.34% and annual incidence
0.43%; ICER = €21,000/QALY). In IDUs, (undiagnosed
prevalence 6.69%, annual incidence of 1.08%), all strategies
are cost-effective, with ICERs ranging from €26,000 to €30,000
per QALY. Additional results from the risk group analysis are
provided in Table 4.
Additional Sensitivity Analyses
In a series of one-way sensitivity analyses (Figure 1), we
varied each of the key parameters across plausible ranges,
while holding all other input values at baseline. The three
parameters that caused the greatest change in the ICER for
one-time screening were: linkage to care, the costs of ART,
and HIV screening costs, but the ICER of one-time, routine,
nationwide screening remained less than €46,800 (three times
the Portuguese GDP of €15,600). (Additional one-way
sensitivity analyses are reported in Appendix S1.)
We then examined the effects of varying these most
influential parameters simultaneously. At the baseline testing
cost of €6, one-time screening is cost-effective whenever
linkage to care exceeds 20%; this persists across the range of
ART costs we considered. However, when testing costs are
increased to €37 and ART costs are held at their baseline
value, one-time routine screening is cost-effective only at
linkage to care rates greater than 40%. At current ART and HIV
test costs, one-time screening is cost-effective for HIV
prevalence levels greater than 0.1% (undiagnosed HIV
prevalence 0.03%). When the test cost is increased to €37, one
time testing is cost-effective at an overall HIV prevalence of
Table 1 (continued).
SD: standard deviation; MSM: men who have sex with men; IDUs: injection drug users; ART: antiretroviral therapy
* A sensitivity analysis was conducted on the product of probability of test offer and probability of test acceptance. We assigned a baseline value of 80% x 79% = 63% to this
product and assumed a range of 32% to 100% for the sensitivity analysis.
doi: 10.1371/journal.pone.0084173.t001
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0.3% (undiagnosed HIV prevalence 0.09%) or greater. (Further
sensitivity analyses are reported in Appendix S1.)
Impact of Expanded Screening on Secondary HIV
Transmission
The addition of a national, one-time screen reduces the
number of secondary transmissions by 4.9% over ten years.
Screening every three years further reduces the number of
secondary cases by 5.3%, while screening annually reduces
the number of secondary cases over ten years by an additional
6.1% (see Appendix S1). When these HIV transmission effects
are taken into account, screening every 3 years is cost-
effective in six regions- including the four with the highest
undiagnosed HIV prevalence and incidence (Porto, Faro,
Setúbal and Lisboa, Table 3).
Discussion
One-time, routine, voluntary HIV screening in the Portuguese
general population meets widely cited international standards
of cost-effectiveness. More frequent screening among high-risk
populations and in the four geographic regions with the highest
HIV prevalence/incidence is also cost-effective. Among both
MSM and IDUs, the returns to increased investment in
screening are virtually proportional to incidence, suggesting
that screening in these populations as often as yearly is
warranted. Previous studies have demonstrated the cost-
effectiveness of expanded testing in the specific context of
middle-income countries (South Africa) and high-income
countries (France, US) [12,13,17]. In the former case, cost-
effectiveness was largely related to the low cost of ART and
the very high burden of disease; in the latter case, results were
driven in large measure by national income and the
consequent willingness to pay for relatively small health gains.
Portugal represents an intermediate case – a nation which, like
many others, benefits from neither low ART prices nor very
high GDP but which still bears the burden of a relatively high
HIV prevalence and incidence. It is instructive, therefore, to find
that a one-time, routine, voluntary HIV screening in the
Portuguese general population still meets international
standards of cost-effectiveness.
There is no universally accepted definition for a “cost-
effective” ICER. The WHO offers general guidance and states
that an ICER that is less than one time the per capita GDP for
a specific country is “very cost-effective” in that context, and an
ICER that is less than three times the per capita GDP is “cost-
effective” [50]. These thresholds have been widely used to take
Table 2. Base Case: Routine HIV Screening in Portuguese National Population.
Variable Current Practice One-Time Screening Screening Every Three Years Annual Screening
General population
Mean undiscounted life expectancy, LM 465.14 465.19 465.24 465.29
Mean discounted life expectancy, LM 194.40 194.42 194.44 194.45
Mean undiscounted quality-adjusted life expectancy, QALM 464.86 464.90 464.96 465.00
Mean discounted quality-adjusted life expectancy, QALM 194.31 194.32 194.34 194.35
Mean discounted lifetime costs per person, €1 630 680 740 810
HIV-infected population
Mean CD4 at detection, all cases (cells/µL) 293 306 353 398
Mean undiscounted life expectancy, LM2 407.84 414.29 422.78 428.76
Mean discounted life expectancy, LM2 177.98 181.05 183.25 185.44
Mean undiscounted quality-adjusted life expectancy, QALM2 367.76 373.36 381.42 387.14
Mean discounted quality-adjusted life expectancy, QALM2 164.09 166.83 168.93 170.96
Mean discounted lifetime costs per person, €1 91,410 97,610 103,740 109,680
Reduction in secondary cases over ten years --- 4.9% 5.3% 6.1%
QALM associated with transmission, discounted 70.00 70.01 70.02 70.02
Costs associated with transmission, discounted1 110 130 140 150
Incremental cost-effectiveness ratios, €/QALY3
Without secondary transmission4 --- 30,000 50,000 65,000
With secondary transmission5 --- 28,000 44,000 59,000
1 Costs are rounded to the nearest €10.
2 Life-expectancy for HIV-infected represents the average life expectancy for all persons who have ever had HIV infection from the time of model entry.
3 ICERs are rounded to the nearest €1,000/QALY. The comparator strategy is always the next smallest, not dominated, alternative.
4 Incremental cost-effectiveness without secondary transmission = (cost per person in strategy 2 - cost per person in strategy 1)/ (QALMs per person in strategy 2 - QALMs
per person in strategy 1)*12.
5 Incremental cost-effectiveness with secondary transmission = [(cost per person in strategy 2 + cost accrued per transmission in strategy 2) – (cost per person in strategy 1
+ cost accrued per transmission in strategy 1)]/[(QALMs per person in strategy 2 + QALMs accrued per transmission in strategy 2) – (QALMs per person in strategy 1 +
QALMs accrued per transmission in strategy 1)].
LM: life month; QALM: quality-adjusted life month; QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio
doi: 10.1371/journal.pone.0084173.t002
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into account national ability to pay. In Portugal, this sets a limit
for an ICER to be considered cost-effective at $46,800.
Anecdotal evidence suggests that the Portuguese National
Authority of Medicines (Infarmed) adopts an informal threshold
of €30,000/QALY in determining whether a given
pharmaceutical intervention is cost-effective. This threshold is
inspired by the United Kingdom National Institute for Health
and Clinical Excellence (NIHCE) guidelines [51]. Our ICER
estimate for a national one-time screening is just under that
threshold. Thus, one-time, routine, voluntary HIV screening in
the general population meets both widely cited international
standards and informally understood standards of cost-
effectiveness in Portugal. However, given the challenges of
national implementation, as well as constrained resources, it
may prove both practical and expedient to begin by initiating
routine HIV screening first among IDUs and MSM and in the
four high-prevalence regions, where the ICERs are
unequivocally favorable, both by formal and informal standards.
At €28,000/QALY, the cost-effectiveness ratio for one-time,
nation-wide screening in Portugal stands in contrast to higher
ICERs, which we have previously obtained using similar
methods and national data from both France (€60,400/QALY)
and the United States (€67,400/QALY) [12,13,17]. These
differences are explained by Portugal’s higher levels of
undiagnosed HIV prevalence, higher HIV incidence, lower
mean CD4 counts at presentation to care under current
practices of HIV detection, and lower costs of HIV screening.
Each of these differences leads to more favorable cost-
effectiveness ratios for one-time routine screening in Portugal
than in France or the United States [12,13,17].
While instructive to note the differences between this
analysis and previous findings, it is also useful to highlight
important qualitative similarities. First, we once again find that
Table 3. Results: Regional Analysis of Routine HIV Screening in Portugal.
Region
Undiagnosed HIV
Prevalence, %
Annual HIV
Incidence, (/100 PY) ICER (€/QALY) ICER (€/QALY)
   
Without accounting for secondary
transmission Accounting for secondary transmission
   One-Time Screening   
Screening Every Three
Years One-Time Screening   
Screening Every Three
Years
Guarda 0.03 0.005 40,000 97,000 36,000 96,000
Viana do Castelo 0.04 0.008 36,000 71,000 33,000 67,000
Vila Real 0.05 0.007 34,000 86,000 31,000 83,000
Viseu 0.05 0.009 34,000 71,000 33,000 91,000
Castelo Branco 0.05 0.011 31,000 66,000 29,000 61,000
Bragança 0.06 0.008 33,000 77,000 31,000 75,000
Braga 0.06 0.009 35,000 67,000 31,000 64,000
Aveiro 0.06 0.017 33,000 53,000 30,000 48,000
Açores 0.06 0.021 36,000 48,000 31,000 42,000
Portalegre 0.07 0.004 34,000 120,000 30,000 60,000
Évora 0.07 0.005 30,000 274,000 30,000 243,000
Coimbra 0.08 0.014 31,000 57,000 29,000 52,000
Beja 0.09 0.002 34,000 308,000 38,000 488,000
Leiria 0.09 0.015 34,000 56,000 31,000 50,000
Santarém 0.09 0.017 31,000 53,000 29,000 48,000
Madeira 0.09 0.023 33,000 47,000 30,000 41,000
Porto 0.19 0.031 30,000 45,000 28,000 39,000
Faro 0.21 0.035 29,000 41,000 27,000 35,000
Setúbal 0.26 0.030 32,000 41,000 30,000 36,000
Lisboa 0.29 0.046 28,000 40,000 27,000 34,000
1. ICERs are rounded to the nearest €1,000/QALY. The comparator strategy is always the next smallest, not dominated, alternative.
2. Dominated: less effective and more costly than some combination of alternative strategies, for the same region.
ICER: incremental cost-effectiveness ratio; QALY: quality-adjusted life year
doi: 10.1371/journal.pone.0084173.t003
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population-wide routine HIV screening is easily justified as a
comparatively attractive use of scarce health resources.
Second, we see that the cost-effectiveness of HIV screening is
surprisingly insensitive to both the prevalence of undetected
HIV in the target population and the cost of the HIV test. At
current ART costs, only at undetected HIV prevalence levels
less than or equal to 0.09% (overall prevalence of 0.3%) do the
costs of counseling and testing itself begin to affect decision
Table 4. HIV Screening in High Risk Groups in Portugal.
Variable Current Practice One-Time Screening Screening Every Three Years Annual Screening
Men who have sex with men (undiagnosed HIV prevalence = 3.34%, annual HIV incidence = 0.43%)
General population
Mean undiscounted life expectancy, LM 510.33 511.00 511.71 512.26
Mean discounted life expectancy, LM 202.94 203.28 203.45 203.67
Mean undiscounted quality-adjusted life expectancy, QALM 504.13 504.73 505.41 505.92
Mean discounted quality-adjusted life expectancy, QALM 200.82 201.12 201.28 201.49
Mean discounted lifetime costs per person, €1 14,830 15,500 16,060 16,650
HIV-infected population
Mean undiscounted life expectancy, LM2 426.07 430.72 435.56 439.58
Mean discounted life expectancy, LM2 183.40 185.77 187.01 188.52
Mean undiscounted quality-adjusted life expectancy, QALM2 382.52 386.64 391.23 395.05
Mean discounted quality-adjusted life expectancy, QALM2 168.49 170.59 171.76 173.20
Mean discounted lifetime costs per person, €1 104,170 109,030 112,710 116,770
Percent reduction in secondary cases over ten years, % --- 3.21 3.44 4.41
QALM associated with transmission, discounted 794.42 795.55 796.01 796.66
Costs associated with transmission, discounted2 23,110 25,490 25,630 26,280
Incremental cost-effectiveness ratios, €/QALY3
Without secondary transmission4 --- 26,000 Dominated6 37,000
With secondary transmission5 --- Dominated6 Dominated6 21,000
Injection drug users (undiagnosed HIV prevalence = 6.69%, annual HIV incidence = 1.08%)
General population
Mean undiscounted life expectancy, LM2 356.82 358.52 361.41 363.31
Mean discounted life expectancy, LM2 169.17 170.08 170.95 171.66
Mean undiscounted quality-adjusted life expectancy, QALM2 346.70 348.23 350.94 352.73
Mean discounted quality-adjusted life expectancy, QALM2 165.14 165.96 166.77 167.44
Mean discounted lifetime costs per person, €1 24,960 26,840 29,280 31,370
HIV-infected population
Mean undiscounted life expectancy, LM2 324.55 330.21 339.86 346.27
Mean discounted life expectancy, LM2 160.00 163.07 165.98 168.35
Mean undiscounted quality-adjusted life expectancy, QALM2 290.69 295.74 304.80 310.85
Mean discounted quality-adjusted life expectancy, QALM2 146.49 149.26 151.99 154.23
Mean discounted lifetime costs per person, €1 83,730 89,910 98,030 104,960
Percent reduction in secondary cases over ten years -- 4.64 6.72 7.46
QALM associated with transmission, discounted 81.65 82.09 82.32 82.56
Costs associated with transmission, discounted2 4,470 5,360 5,380 5,560
Incremental cost-effectiveness ratios, €/QALY3
Without secondary transmission4 -- 28,000 36,000 38,000
With secondary transmission5 -- 26,000 28,000 30,000
1 Costs are rounded to the nearest €10.
2 Life-expectancy for HIV-infected represents the average life expectancy for all persons who have ever had HIV infection from the time of model entry.
3 ICERs are rounded to the nearest €1,000/QALY. The comparator strategy is always the next smallest, not dominated, alternative.
4 Incremental cost-effectiveness without secondary transmission = (cost per person in strategy 2 - cost per person in strategy 1)/ (QALMs per person in strategy 2 - QALMs
per person in strategy 1)*12.
5 Incremental cost-effectiveness with secondary transmission = [(cost per person in strategy 2 + cost accrued per transmission in strategy 2) – (cost per person in strategy 1
+ cost accrued per transmission in strategy 1)]/[(QALMs per person in strategy 2 + QALMs accrued per transmission in strategy 2) – (QALMs per person in strategy 1 +
QALMs accrued per transmission in strategy 1)].
6 Dominated: higher cost-effectiveness ratio compared to preceding strategy.
LM: life month; QALM: quality-adjusted life month; QALY: quality-adjusted life year; ICER: incremental cost-effectiveness ratio
doi: 10.1371/journal.pone.0084173.t004
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making [23,52]. Finally, we once again find that secondary
transmission effects – while notable when measured on a
population-wide basis over a long time horizon – exert minimal
influence on the cost-effectiveness ratio [12].
This study has several limitations. First, the results are based
on a mathematical model that estimates long-term
consequences of different strategies based on data from
multiple sources, some of which by necessity are not
Portuguese. For example, the proportion of undiagnosed HIV
cases (30%) is based on estimates for Europe and is not
specific to Portugal [2]. Moreover, in the absence of available
data in our regional population analysis, we assumed that the
background testing rate is the same for all regions. The
sensitivity analyses on these and other input parameters
demonstrate that the results are robust to variations in these
assumptions. However, while these sensitivity analyses were
conducted to manage the uncertainties in our input data
assumptions, a more complete exploration would have
included a probabilistic sensitivity analysis (PSA), providing a
cost-effectiveness acceptability curve showing the probability of
cost-effectiveness of one-time screening against varying
willingness-to-pay threshold values. Recognizing the difficulties
of conducting PSA alongside a Monte Carlo microsimulation
such as ours, we have adhered as closely as possible to the
guidance of both the US Panel on Cost-effectiveness in Health
and Medicine and the joint SMDM- ISPOR Task Force on
Good Modeling Practice, both of which endorse the use of
deterministic methods—as the one we have performed—to
manage uncertainty [19,45,46]. Second, although we did
account for the effect of HIV RNA levels on transmission, the
population-level data we used for the heterosexual and IDU
groups were based on a meta-analysis of studies of
heterosexual, serodiscordant couples [24]. While we applied a
multiplier to do this for our MSM analysis, this multiplier came
from a model-based rather than a cohort study [25].
Furthermore, we only simulated first-order transmissions rather
Figure 1.  One-Way Sensitivity Analysis on Cost-Effectiveness of One-Time, Routine, National HIV Screening in
Portugal.  The width of the bar is the variation in the incremental cost-effectiveness ratio associated with alternative parameter
values for that input, when secondary transmissions are taken into account. The numbers in parentheses next to each parameter on
the y-axis indicate the base case value, and the numbers in brackets indicate the lower and upper-bounds used in the sensitivity
analyses. QALY: quality-adjusted life year. ICER: incremental cost-effectiveness ratio.
doi: 10.1371/journal.pone.0084173.g001
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than use a fully dynamic HIV transmission model. Therefore,
we may have under-represented the rates of infection and,
therefore, the cost-effectiveness of HIV testing in high-risk
populations. However, varying the probabilities of HIV
transmission widely in sensitivity analyses produced no change
in the cost-effectiveness of one-time routine screening. Finally,
while we project that routine HIV testing will be cost-effective,
this does not imply that it will necessarily be affordable; budget
impact analysis will be a useful next step for budget planning
[53].
In summary, we find that one-time routine HIV screening of
the national population is a cost-effective intervention for
Portugal. More frequent screening in higher-risk regions and
subpopulations is also justified on both clinical and cost-
effectiveness grounds. In light of Portugal’s current economic
challenges, focusing on screening higher-risk populations and
geographic settings should be a priority.
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